Spondyloarthritis & psoriatic arthritis
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA ‐2 Trial
Authors' conclusion
Deucravacitinib was well tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient-reported outcomes, including functional ability and quality of life. Clinical responses and patient-reported outcomes were maintained through W52.
Study context
- Population
- Patients with PsA naive to bDMARDs or who received TNFirandomised
- Participants
- 729 patients
- Comparison
- Deucravacitinib 6 mg daily vs placebo through W16
- Deucravacitinibn = 312
- Placebon = 312reference
- Apremilastn = 105
- Primary endpoint
- ACR20 response
- Follow-up
- W16
Methodological detailsdouble-blind, placebo-controlled, phase 3, apremilast safety reference arm
- Double-blind
- Placebo-controlled
- Phase 3
- Apremilast safety reference arm
Primary result
As reported in the abstract
ACR20
P = 0.0002
Secondary outcomes
- ACR20 maintained through W52 — Deucravacitinib
- 62.2%
- ACR20 maintained through W52: Placebo-deucravacitinib 67.3%
Hierarchical secondary endpoints (HAQ-DI, PASI 75, SF-36 PCS, MDA) · W16
- Significant differences in deucravacitinib vs placebo
- Analysed per prespecified order to control for multiplicity
Safety
Serious adverse events · W16
New safety signals, deaths, cardiovascular events, malignancies, opportunistic infections · through W52
- No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections
Original publication
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA ‐2 Trial. Arthritis Rheumatol. Published 20 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →